Pre-Submission Review for Hepatology Papers

Hepatology reviewers usually ask:

• is the liver-disease phenotype defined consistently?
• does the endpoint match the clinical claim?
• are fibrosis, steatosis, portal-hypertension, transplant, or viral markers measured credibly?
• is the cohort strong enough for subgroup or prognostic claims?
• are competing risks, confounding, and missing data handled clearly?
• are CONSORT, STROBE, PRISMA, STARD, or other reporting expectations met?
• does the paper fit hepatology, general GI, transplant, metabolic disease, oncology, or broader medicine?

Those questions decide whether the paper looks ready or just technically complete.

In our pre-submission review work, hepatology papers most often need revision before submission for five reasons.

Endpoint inflation: the manuscript discusses decompensation, survival, transplant, or practice change, but the actual endpoint is a weaker lab, imaging, elastography, or short-term surrogate.

Phenotype drift: metabolic liver disease, alcohol-associated liver disease, viral hepatitis, cholestatic disease, or transplant populations are mixed without enough stratification.

Biomarker overreach: a model, score, imaging feature, or omics signature is promising, but validation is too thin for the claim.

Subgroup fragility: the headline result depends on a small subgroup, center-specific practice, or post-hoc cut point.

GI-versus-hepatology mismatch: the paper is framed for a broad GI audience when the real contribution is a liver-specific methods or disease-lane point.

The review should identify which failure pattern controls the submission decision.

Journal of Hepatology's public author guidance endorses appropriate reporting guidelines and says papers outside scope or not strong enough can be returned without detailed review. That is the field's practical first screen: before reviewers debate details, editors assess whether the manuscript is clear, well reported, and strong enough for the journal's liver audience.

For authors, the lesson is simple. A hepatology manuscript must make its disease lane and endpoint logic obvious before the editor reaches the methods details.

Send the manuscript, target journal, figures, tables, supplement, statistical analysis plan, reporting checklist, study protocol if available, ethics statement, trial registration if relevant, data availability statement, and any prior decision letter.

For liver papers, also send phenotype definitions, fibrosis or steatosis methods, endpoint definitions, follow-up timing, transplant or decompensation definitions, and codebook notes for derived variables. If the paper includes imaging or pathology, include representative images and legends.

A useful hepatology pre-submission review should include:

• liver-disease lane verdict
• endpoint-to-claim alignment
• cohort and statistical-risk notes
• fibrosis, steatosis, viral, transplant, or biomarker critique where relevant
• reporting checklist gaps
• target-journal fit
• submit, revise, retarget, or diagnose deeper call

The output should not only make the prose cleaner. It should tell the authors whether the liver-specific evidence package can survive review.

Before submission, hepatology authors often need to:

• define phenotype and disease stage more precisely
• separate exploratory and confirmatory claims
• narrow conclusions around surrogate endpoints
• add sensitivity analyses for missing data or confounding
• clarify follow-up windows and censoring
• improve biomarker, elastography, imaging, or pathology figure legends
• add reporting checklist items
• retarget from flagship hepatology to a specialty liver, GI, or general medical journal

These are readiness fixes. They usually matter more than final wording.

Hepatology review is most worth it when one wrong submission cycle would be expensive. That usually means a selective liver journal, a clinical deadline, a fellowship or faculty package, a high-cost cohort, or a study where the endpoint decision is debatable.

Use review before submission when:

• the target is Journal of Hepatology, Hepatology, Gut, Gastroenterology, or another selective liver or GI journal
• the paper makes a practice-facing claim from observational data
• the main result depends on a fibrosis, steatosis, biomarker, imaging, or transplant endpoint
• subgroup findings are central to the abstract
• the study has been rejected once and the team is unsure whether to revise or retarget

Skip paid review when the manuscript still needs obvious internal work: incomplete methods, missing tables, unresolved author disagreement, or an endpoint definition that the team has not finalized. A reviewer can identify those problems, but the better move is often to fix the known issues first and then review the near-submission version.

Use this page when the manuscript's main risk is liver-specific. Use the gastroenterology page when the main risk is clinical GI, endoscopy, IBD, functional disorders, or broad digestive-disease framing.

Hepatology deserves its own owner because liver papers have separate endpoint logic, disease staging, transplant relevance, and biomarker expectations. The page should not become a full submission guide for one hepatology journal.